CIViC Evidence Items

61 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline

BClinical — prospective trial or retrospective cohort study

CCase study — single case report or small case series

DPreclinical — in vitro or animal model data

EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

	Predictive	Diagnostic	Prognostic	Functional	Predispos.	Oncogenic
BCR::ABL1	323	11
BRAF	186	4	26	2		1
EGFR	248		12	3		2
EML4::ALK	64
ERBB2	142		2
FLT3	55	2	21
KIT	102	3	7
KRAS	159	4	24			4
PIK3CA	156		16	4
PTEN	53	1	3	1	2	1
TP53	52		40	100	2
VHL	5	2	3		635	15

Predictive:Links a variant to treatment response or resistance

Diagnostic:Supports or refutes a specific disease diagnosis

Prognostic:Informs disease progression or clinical outcome

Functional:Characterises the biological effect of a variant

Predisposing:Germline variant associated with cancer predisposition

Oncogenic:Characterises the variant's role in oncogenesis

Level	Gene	Variant	Type	Direction	Significance	Disease	Drugs	Source
D	PTEN	R233*	Predictive	Supports	Sensitivity/Response	Breast Cancer	MTOR Inhibitor	Courtney et al., 2010
B	PTEN	Deletion	Prognostic	Supports	Poor Outcome	Prostate Adenocarcinoma		Yoshimoto et al., 2007
D	PTEN	Loss	Predictive	Supports	Sensitivity/Response	Prostate Cancer	Temsirolimus	Neshat et al., 2001
B	PTEN	Loss	Predictive	Supports	Resistance	Bladder Carcinoma	Everolimus	Seront et al., 2013
D	PTEN	Loss	Predictive	Supports	Resistance	Breast Cancer	Alpelisib	Juric et al., 2015
B	PTEN	Expression	Predictive	Supports	Sensitivity/Response	Glioblastoma	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Mellinghoff et al., 2005
B	PTEN	Loss	Predictive	Supports	Sensitivity/Response	Her2-receptor Positive Breast Cancer	Everolimus	André et al., 2016
B	PTEN	Deletion	Prognostic	Supports	Poor Outcome	Prostate Cancer		Gao et al., 2016
D	PTEN	Loss	Predictive	Supports	Resistance	Melanoma	Vemurafenib	Shi et al., 2014
D	PTEN	Loss	Predictive	Supports	Resistance	Her2-receptor Positive Breast Cancer	Lapatinib	Eichhorn et al., 2008
B	PTEN	R233*	Prognostic	Does Not Support	Poor Outcome	Glioblastoma		Carico et al., 2012
B	PTEN	Loss	Predictive	Supports	Resistance	Colorectal Cancer	Cetuximab	De Roock et al., 2011
C	PTEN	Loss	Predictive	Supports	Sensitivity/Response	Cancer	Paclitaxel,Carboplatin,Buparlisib	Hyman et al., 2015
B	PTEN	Loss	Predictive	Does Not Support	Resistance	Endometrial Cancer	Ridaforolimus,Temsirolimus	Mackay et al., 2014
B	PTEN	Expression	Predictive	Supports	Sensitivity/Response	Breast Cancer	Trastuzumab	Fujita et al., 2006
B	PTEN	Expression	Predictive	Supports	Sensitivity/Response	Glioblastoma	Erlotinib,Gefitinib	Mellinghoff et al., 2005
B	PTEN	Deletion	Predictive	Supports	Sensitivity/Response	Prostate Cancer	Everolimus	Templeton et al., 2013
B	PTEN	Mutation	Predictive	Does Not Support	Sensitivity/Response	Endometrial Carcinoma	Everolimus	Trédan et al., 2013
B	PTEN	Loss	Predictive	Supports	Resistance	Her2-receptor Positive Breast Cancer	Trastuzumab	Esteva et al., 2010
B	PTEN	Loss	Predictive	Does Not Support	Resistance	Her2-receptor Positive Breast Cancer	Trastuzumab	Esteva et al., 2010
D	PTEN	Loss	Predictive	Supports	Sensitivity/Response	Her2-receptor Positive Breast Cancer	Trastuzumab,PI3K/BET Inhibitor LY294002	Nagata et al., 2004
D	PTEN	Mutation	Predictive	Supports	Resistance	Head And Neck Squamous Cell Carcinoma	Taselisib	Zumsteg et al., 2016
D	PTEN	Mutation	Predictive	Supports	Sensitivity/Response	Cancer	Ipatasertib	Lin et al., 2013
D	PTEN	Loss	Predictive	Supports	Sensitivity/Response	Cancer	Capivasertib	Davies et al., 2012
D	PTEN	Mutation	Predictive	Supports	Sensitivity/Response	Prostate Adenocarcinoma	Alpelisib,PI3Kbeta Inhibitor AZD8186,Enzalutamide	Schwartz et al., 2015
D	PTEN	V317FS	Predictive	Supports	Sensitivity/Response	Skin Melanoma	MEK Inhibitor CI-1040,Akt Inhibitor MK2206	Turajlic et al., 2014
D	PTEN	Loss	Predictive	Does Not Support	Sensitivity/Response	Breast Cancer	Everolimus,MTOR Kinase Inhibitor PP242	Weigelt et al., 2011
D	PTEN	Loss	Predictive	Supports	Sensitivity/Response	Endometrial Cancer	Temsirolimus	Weigelt et al., 2013
D	PTEN	R173C	Predisposing	Supports	Uncertain Significance	Cancer		Han et al., 2000
C	PTEN	R173C	Predisposing	Supports	Predisposition	Obsolete PTEN Hamartoma Tumor Syndrome		Hopman et al., 2012
D	PTEN	Loss	Predictive	Supports	Sensitivity/Response	Her2-receptor Positive Breast Cancer	Pictilisib	O'Brien et al., 2010
B	PTEN	Loss	Predictive	Does Not Support	Sensitivity/Response	Cancer	Everolimus	Kim et al., 2017
B	PTEN	Loss	Predictive	Supports	Resistance	Colorectal Cancer	Panitumumab,Cetuximab	Sartore-Bianchi et al., 2009
B	PTEN	Loss	Predictive	Does Not Support	Resistance	Her2-receptor Positive Breast Cancer	Trastuzumab Emtansine	Baselga et al., 2016
D	PTEN	C136R	Functional	Supports	Loss of Function			He et al., 2013
D	PTEN	Loss	Predictive	Supports	Sensitivity/Response	Melanoma	Uprosertib	Lassen et al., 2014
D	PTEN	Loss	Predictive	Supports	Sensitivity/Response	Breast Cancer	PI3Kbeta Inhibitor AZD8186	Hancox et al., 2015
D	PTEN	Expression	Predictive	Supports	Sensitivity/Response	Glioblastoma	Dacomitinib	Zahonero et al., 2015
B	PTEN	Loss	Predictive	Supports	Resistance	Gastric Adenocarcinoma	Trastuzumab,Lapatinib	Zhang et al., 2015
C	PTEN	Loss	Predictive	Supports	Sensitivity/Response	Pancreatic Carcinoma	Akt Inhibitor MK2206	Yap et al., 2011
D	PTEN	Mutation	Predictive	Does Not Support	Sensitivity/Response	Head And Neck Cancer	Pictilisib,Tanespimycin	Wirtz et al., 2015
D	PTEN	Loss	Predictive	Supports	Resistance	Her2-receptor Positive Breast Cancer	Trastuzumab	Berns et al., 2007
D	PTEN	Loss	Predictive	Supports	Resistance	Ovarian Cancer	Cisplatin	Lee et al., 2005
B	PTEN	Loss	Predictive	Supports	Resistance	Stomach Carcinoma	Chemotherapy	Oki et al., 2005
D	PTEN	R130*	Predictive	Supports	Sensitivity/Response	Thyroid Cancer	Perifosine,Temsirolimus	Liu et al., 2009
C	PTEN	Mutation	Diagnostic	Supports	Positive	Glioblastoma		Rasheed et al., 1997
B	PTEN	Loss	Predictive	Supports	Resistance	Her2-receptor Positive Breast Cancer	Trastuzumab	Razis et al., 2011
B	PTEN	Loss	Predictive	Supports	Resistance	Breast Cancer	Trastuzumab	Razis et al., 2011
D	PTEN	Loss	Predictive	Does Not Support	Sensitivity/Response	Breast Cancer	Pictilisib	O'Brien et al., 2010
B	PTEN	Loss	Predictive	Does Not Support	Sensitivity/Response	Solid Tumor	Paclitaxel,Buparlisib,Carboplatin	Smyth et al., 2017

Page 1 of 2